LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Listă Acțiuni・MacroGenics Inc

MacroGenics Inc

Închisă

SectorSănătate

4.21 1.94

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

4.03

Maxim

4.34

Indicatori cheie
By Trading Economics
Venit	-31M -14M
Vânzări	-32M 41M
EPS	-0.22
Marjă de profit	-34.333
Angajați	293
EBITDA	-37M -15M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+83.48% upside

Dividende
By Dow Jones
Următoarele câștiguri	19 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	65M 188M
Deschiderea anterioară	2.27
Închiderea anterioară	4.21

Sentimentul știrilor

By Acuity

35%

65%

112 / 346 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

1.47 / 1.64 Suport & Rezistență

MacroGenics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 mai 2026, 22:44 UTC

Achiziții, Fuziuni, Preluări

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mai 2026, 22:27 UTC

Achiziții, Fuziuni, Preluări

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mai 2026, 22:12 UTC

Câștiguri

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mai 2026, 21:52 UTC

Achiziții, Fuziuni, Preluări

LVMH to Sell Marc Jacobs

15 mai 2026, 00:00 UTC

Câștiguri

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mai 2026, 23:57 UTC

Achiziții, Fuziuni, Preluări

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mai 2026, 23:56 UTC

Achiziții, Fuziuni, Preluări

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mai 2026, 23:56 UTC

Achiziții, Fuziuni, Preluări

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mai 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14 mai 2026, 23:56 UTC

Achiziții, Fuziuni, Preluări

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mai 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mai 2026, 23:47 UTC

Câștiguri

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mai 2026, 23:47 UTC

Câștiguri

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mai 2026, 23:46 UTC

Câștiguri

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mai 2026, 23:46 UTC

Câștiguri

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mai 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mai 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 mai 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mai 2026, 22:11 UTC

Achiziții, Fuziuni, Preluări

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mai 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mai 2026, 22:04 UTC

Câștiguri

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mai 2026, 22:04 UTC

Câștiguri

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mai 2026, 22:04 UTC

Câștiguri

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mai 2026, 22:00 UTC

Câștiguri

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mai 2026, 21:55 UTC

Câștiguri

Nu Holdings 1Q EPS 18c >NU

14 mai 2026, 21:55 UTC

Câștiguri

Nu Holdings 1Q Rev $4.97B >NU

Comparație

Modificare preț

MacroGenics Inc Așteptări

Obiectiv de preț

By TipRanks

83.48% sus

Prognoză pe 12 luni

Medie 6.33 USD 83.48%

Maxim 9 USD

Minim 4 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMacroGenics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor MacroGenics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

1.47 / 1.64Suport & Rezistență

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

112 / 346 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.